There are a wide variety of benefits associated with SGLT‐2 inhibitor use in type 2 diabetes, including significant reduction in haemoglobin A1C, reduction in major cardiovascular adverse events (MACE) and significant reduction in the risk of end‐stage kidney disease compared to placebo.2, 3, 4. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.